Unaudited Financial Results along with Limited Review Report as submitted by the statutory auditor of the Company for the Third Quarter and Nine Months Ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Limited, a Mumbai-based pharmaceutical company, reported Q3 FY26 standalone revenue from operations of Rs 2,086.32 lacs, up ~20% YoY from Rs 1,734.91 lacs, while consolidated revenue grew ~27% YoY to Rs 2,206.29 lacs. Standalone net profit for Q3 jumped ~38% YoY to Rs 261.67 lacs and consolidated PAT rose ~46% YoY to Rs 277.63 lacs, indicating strong margin expansion. For 9M FY26, standalone revenue rose ~4.5% YoY to Rs 5,425.27 lacs and PAT rose ~1.3% YoY to Rs 598.58 lacs, with consolidated 9M PAT at Rs 614.54 lacs (~4% YoY). Statutory auditor R.B. Gohil & Co. issued an unmodified limited review report on both standalone and consolidated statements. Management highlighted the new Pune IV Fluid plant commencing commercial dispatches with a 90-day forward order book, 77% export share across 20 countries, and entry into three additional countries after regulatory audits; EPS was slightly diluted due to warrant conversion expanding the equity base.
Strong Q3 profit growth of ~38-46% YoY outpacing revenue signals healthy operating leverage and easing of prior quarter challenges, which is positive for shareholders. The Pune IV plant ramp-up and new geographic entries provide visible multi-quarter revenue tailwinds.